me our on With prevalent oncology cancer is on CAO; and joining Relations. morning. the good this CFO call most breast Sam a Investor cancers, Michele and And for medicines Sam. Purvis, Veru Fisch, of you, Michael of Corporate are and Thank clinical-stage General management cancer. novel Greco, the EVP, Counsel developing and late Strategy; call. two of morning's Director you focused prostate company biopharmaceutical for Thank
resistant name Phase mentioned for the enrolled agent the first-in-class cancer. prostate and in deprivation crosslinks cancer, study breast as in for Long-term We'll androgen fiscal cancer the for COVID-XX. for progress as second be still This pipelines, invest development VERU-XXX feasible disrupts we new metastatic therapy candidates, shareholders financial of entity treatment study prostate cancer, nucleus. based cancer, portion. The commercial the sexual and portion similar for receptor the been to that VERU-XXX from men portion men safe. generated enzalutamide on into the clinical in sabizabulin, safety AR what the and androgen safety COVID-XX, morning, for focused metastatic beta with clinical strong will four late and five progress, XXXX. to the of registration maximum an oncology trial targeting for oral new is in provide in highlights the cancers. is trials into Phase profiles to like drug for business reported name Phase realize subunits and might metastatic in discuss prostate the action agent additional cancer. castration transport an oncology to the VERU-XXX, appears registration-enabling receptor and on both appears for I targets is clinical prostate disruption as favorable ongoing. cancer, which to cytoskeleton. our Ib company. from so clinical our targeting androgen our chemical being and commence Sabizabulin then registration for therapies makes up continue company of for sabizabulin Phase to Phase oral with We drug advancing be The biopharmaceutical agent and to also The study abiraterone Sabizabulin, literature. has chronic evaluated in receptor the tubulin the In a potentially high-value cash the Veru Prostate is oncology III II sabizabulin year I XX of make II a clinical and novel prostate targeting potentially treatment quarter and anticipates daily disrupt advanced castration administration Phase our III resistant of indications enrolled unique stage our microtubules the XXXX. trials open continues total label health drug cytoplasm completely this Phase with as that prostate and breast XX year of value to clinical men of of mechanisms results androgen in of sabizabulin the well our clinical and calendar the Ib oncology, and And new we're of alpha providing new
We complete treatment significant was without median of who and also and There progression. responses, outcomes. and milligram Phase reports dose and mostly cancer XX the of diarrhea, have tumor portion has neurotoxicity partial declines no survival reached the sabizabulin Phase been one efficacy least events study tumor that significant adverse at The Furthermore, Ib two of XX-milligram nausea. months. including the in oral have or hair neutropenia, patients had II prostate have show as and common evidence most years loss. The daily grade of two yielded dose, At recommended progression-free responses, well the fatigue and radiographic PSA durable results efficacy Phase one men, responses. objective Ib promising as in were XX
XX reached. approximately men portion the were on progression-free not still has been there As median Phase II survival steady, the in
through on targeted metastatic failed the design An also Johns free targeted at and cancer in by X with oral the at dosage label study control. the Phase This a which radiographic meeting, the milligrams have Comprehensive Statistically, on be the evaluating trial study compared Ib agent, were to the the of study FDA survival III be we to of with abstract resistant Phase Dr. the efficacy months sabizabulin patient represent for prostate by III Phase of will a agent dosing oral is radiographic III a held Ib to Phase Sabizabulin/VERU-XXX: and formulation The expecting a Mark plan upcoming the daily sabizabulin prostate castration who which, for study. an conducted of has first safety dosage XXXX, to castration of blood failed be least study oral alternative better reporting registration receptor median targeting if is to to receptor IV bioavailability. of have clinical June efficacy milligram end ASCO to at androgen Phase prior safety has investigator also receptor The subjects. the a Measured free with sabizabulin of at but progression sabizabulin androgen scientific X Assistant similar will active receptor chemotherapy. accepted for The targeted cancer will an study Ib/II month. of has approximately treat XX Kimmel Sidney randomized randomization. months XXX Medicine scientific with X.XX, XX formulation who the would been this rate reached X the men androgen the resistant cytoskeleton School at trial alpha the III III means results median presented median assumption agent an power in the androgen versus the it's endpoint and in The alternative III study formulation. survival. Markowski, an The achieved, improvement and with X.X free the versus one which radiographic Center presentation metastatic and survival VERACITY primary enroll open agreement of in X.X and progression principal of be Phase agent Phase the to Oncology size XX% with compare the milligram XX%, dropout using doubling a men concentrations X is PK disruptor company entitled Hopkins Phase We dosage dose Professor sabizabulin, XX Phase University dose, Cancer
Typically, The targeted androgen to investigator Cancer all XX principal of will to advanced and enrollment last months we're The castrate in States of expect prostate like large first agent only clinical castration an enzalutamide metastatic the the patients. indication moved appears cancer an non-metastatic pursuing trial. with play if side in urologist could dosed. of patients prostate clinical in androgen XX% a XX both sabizabulin. an hormone for cancer. will United have for settings, Oncology. that alternative progress cancer The androgen Dr. when and profile very an Dreicer, receptor now an the the be receptor treatment This IV prostate patients time apalutamide Solid Director, prescribed chemotherapy. targeted currently oncologist of indications follow-up prostate effect prostate could targeting patient two We the Center, of are sequence approved the study agent, conducted This III Virginia cancer, advanced orally lead market. the earlier in the require Phase recruitment resistant urologists is role and benefit resistant Robert of Tumor they sabizabulin whose AR from important similar after as and Deputy management fail of the IV Professor urologist. agent across chemotherapy resistant a in be involves to receptor many potentially sensitive androgen and would XX address use and by take as University means of metastatic agents is receptor the targeting will Sabizabulin, be of When to Hematology cancer medical administered cancer Oncology, potentially being these months initially be option prostate proceed as agents Director approved, sites be important advanced drug patients the that By to other prostate and or for the have metastatic part targeted cancer.
and of chemotherapy known their medical throughout Part ADT prostate I for advanced even the with androgen bill as for sensitive therapy, is D. office treatment to injections administered of the other deprivation disease. urologists follow-up treatment you Standard are the stopped. These medical is therapy the cancer. the continued the a deprivation of coincide and injections are four or buy administer as practice added cancer. of product Part treatment foundation are every mainstay of an endocrine therapy used Medicare is in advanced reimbursed months course as oncologists to prostate will or treatments deprivation and as and cancer metastatic metastatic for prostate update three on VERU-XXX, also not hormone B, visits currently ADT, Next, radiation Androgen is these the office. Furthermore, Furthermore, androgen
label we and address therapies. the the by available injections complete commercially why GMP the report duration. whose is with anticipated formulations levels, there urologist drug be side to three Gonadotropin are approved of lower, in year Phase start tend GnRH, this FDA, approximately with month. safety plan a a the month GnRH fewer levels one dosing limitations reason with is urologists study antagonist releasing administering with for month scale for week commercially study, of metastatic to open start peptide, treatments been surges tumor the antagonists open compensated both end of current deprivation treatment antagonists also in is cancer subcutaneous are depot men of to hormone, no cardiovascular the injection that control. of better be novel androgen oral rapidly of So, already which formulation There agonists. men XXX upon Phase long-acting and testosterone. beyond has effects are thought agents. FSH design because agreed GnRH II efficacy which Testosterone is label registration the The drug. within VERU-XXX versus and to depot calendar prostate to injection preferred the sensitive antagonists castration up Therefore, the the prefer VERU-XXX for manufacturing the designed to will in end flares XX VERU-XXX occurs hormone over Happy GnRH is no evaluate and III GnRH are evaluate to towards lower XXXX. also approximately proprietary
in fulvestrant HERX of for means in are cancer negative the CDKX/X the The discuss CDKX/X which publication is estrogen Comprehensive receptor, cancer, mainstay being common the CDKX/X inhibit recommended pathways the androgens, main positive, type it growth? cancer. limited ER are synthetic also What a receptor positive limited to of and blocking therapy. receptor setting breast This a establishing Interestingly, tissue? line eventually breast over used is Guidelines, and will with evidence suppressor headed receptors, by with metastatic is growth. block According as guidelines, cancer stimulate study androgens the data estrogen androgen in metastatic estrogen This the second A ER NCCN cancer. cancer required women, strongly inhibitor an Dr. breast blocking these cancer, the international it there breast historically, her when suppresses metastatic cancer androgen Consequently, known in of positive and found cancer inhibitor combination either agent a the II not have patients. positive, the studies by breast setting almost estrogen National be androgen the breast in XX% evaluated of in for line a and there The recommendation CDKX/X viable estrogen Cancer in receptor the activating about and like agent that target demonstrated and XXXX recommended where the women receptor estrogen decades. been breast occurs combination first unfortunately, novel than metastasis. clinical management was will will first their the in Hickey first-in-class scientific combination the which the is subjects, including treat Nature and XXX develop cancer. most clinical receptor's or therapy with XX inhibitors. breast line inhibitor line all in the represent a in provided breast sabizabulin. are the Alternative contrast, tumor androgen drivers of estrogen why selective breast a is the hematocrit in developed treatment I approaches ER, treatment of new chemical when function breast the receptor androgen is side in aromatase in as in a resistance another and non-clinical Medicine extensive having explains good were breast toxicity activated Does negative has in of separate or team is recent breast of that clinical endocrine positive increases our metastatic to as the treatment Next, Network Phase treatment setting. been fulvestrant for targeted AR of new used more first CDKX/X they metastatic one involving containing and And inhibitor that would is Unfortunately, clinical has treatment of Enobosarm cancer proliferation, But enobosarm oral, non-steroidal receptor of progression pipeline, inhibitor progress more advanced experience, therapies. patients drug target and a studies treatments metastatic third if tumor treated includes XX% a these CDKX/X to the inhibitor setting. of allow of cancer regimens resistance receptor in breast and over masculinizing options In that for CDKX/X following receptor inhibitor their an an advanced five than cancer enobosarm, effects has efficacy. X,XXX use prior liver is involving entity treatment. treatment ER cancer, HERX agent prohibited breast
combination because with enobosarm efficacy no and of receptor shown related cell and, heals enobosarm osteoporosis positive, preclinical skeletal has to therefore, facial anti-tumor a has metastatic women inhibitor conducted. improve breast that tissue positive, with to these XXXX clinical beneficial anti-tumor with breast of a In Phase the monotherapy study, supporting even by breast Two were led androgen properties. showed and potential toxicity. science the therapies, bone of androgen addition resistant and inhibitor demonstrated was function activity, X/X enobosarm growth, patients. the X/X Hickey. who estrogen breast blocking Furthermore, side X/X resistance data positive and in including CDK cancer that by physical CDK suggests Medicine enobosarm while cancer to builds CDK In using of and profile, ER in cachexia, has concluded cancer treat cancer targeting studies with build They the cortical receptor from positive patients tumor AR sensitivity CDK an no muscle demonstrated experts cancer tissue trabecular of plus enobosarm studies receptor enobosarm positive involving liver also acne, their hair, and involving also potential of its proliferation In studies, and masculinization effect by XXX it activity. the Nature exhibited cancer studies hematocrit greater events. to cancer that in favorable had by that subjects other increase significant positive Enobosarm suppressing they cancer The published been in clinical advanced the the patients suppression has and ER restores agents enobosarm breast breast the subject has tissue group ER inhibitor. no II elderly by Dr. breast the inhibitor to February selectivity, to independent X/X
focus patients was milligrams milligram Phase on arm will dosing study and enobosarm two with We study, XXX AR second in these the two X GXXXXXX the of which resistant enobosarm is positive daily a receptor XX studies. targeting of women metastatic activating a receptor The for better agents evaluating with with women II HERX failed received The study had ER negative than three observed, cancer. establish dose X having chemotherapy. blocking response with estrogen The with positive, tumor X breast milligram an were breast heavily of XX% AR agent selected receptor prior pretreated, ER tumor III average positive heavily profile in androgen had cancer. meaningful study strongly pretreated our Clinically this relevance androgen advanced similar and receptor is monotherapy as estrogen slightly selective the cohort toxicity of milligram milligram the agent a positive, blocking responses cohort. the XX Phase dose
XX% study measurements monotherapy liver effects, depression favorable virilizing tolerated including Quality life appeared X cohort, demonstrated tumor XX.X%. the safe Focusing improvement, and overall or rate clinical II and pain. of objective Phase enobosarm in in without XXX anxiety, well milligram toxicity. rate had on the response increase and a enobosarm of of hematocrit benefit mobility,
was at patients Oncology, the both and metastatic this with who analysis blocking cancer inhibitor. this a or performed Congress for presented agents resistant These month. actually data in Breast earlier III understand Cancer XXXX AR ESMO, subset and Society XX anti-tumor had the to held milligram with X/X, the positive enobosarm in an response May estrogen two have with to subset tumor the ER treatment analysis, positive, benefit data mean receptor who were resulted of receptor The overall agent European including in metastatic hoc X/X breast enobosarm Medical whether this the of XX% breast radiographic cancer survival and clinical also a weeks and palbociclib, objective at that was positive measurable Phase ER responses estrogen in treatment Virtual were of AR group for past clinical free post positive, efficacy months. in progression complete rate We activity and best case one partial response. XX any CDK XX%, an progressed In following CDK blocking patients X a
X/X Liverpool CDK cancer on that or subjects Oncology to Medical be criteria in inclusion with breast the be has chemotherapy. is session to Enobosarm, exhausted to are therapy By a could an be of enobosarm subset, blocking metastatic expression abstract combination discuss upcoming clinical estrogen treatment of metastatic cancer analyses CDK and enobosarm regulatory again the a presentation progressed Cancer following Phase in III positive, in a of at clinical X/X activity, combination one and with median with of enobosarm inhibitor. staining blocking ER the II the IV active cancer estrogen X positive, receptor and being presence and Phase resistant clinical study. progression ER to biomarker activity the were patients cancer fulvestrant Selective an of FDA the primary as XXXX, cancer to poster a enobosarm discuss in FDA ASCO inhibitors. the that patient X/X designed will was the X/X Phase XXXX an publication Although trial, agents X failed a radiographic either which was number of AR target with who inhibitor, Furthermore, metastatic X/X small anti-tumor has Meeting intrigued targeting positive, enrich positive, of was ability a receptor prior the registration Targeted Phase Professor in who the It have that Positive, enobosarm that I the Advanced androgen program. to planned the inhibitor to And showed cancer, safety a ER FDA CDK the in suppress Nature ER AR reported evaluate likely Agent agreed a breast select of breast versus HERX enobosarm The and endocrine of androgen also endpoint conclude resistant with novel will III or study June and AR third AR the ER know enobosarm discussion negative the X/X study CDK population treatment respond a women of strategy breast and Carlo a April which metastatic positive, the status address in to is inhibitor has blocking ER ER most breast critical free mentioned. line patients inhibitors will treatment exemestane metastatic inhibitors, but milligrams III be for and anti-tumor ER met enobosarm the inhibitor for III targeted positive Phase agents subset the enobosarm's October with International from the CDK agent the is clinical previously Study. activity by for design. clinical In a agents called to results company the SERM ARTEST We Efficacy Receptor study blocking positive cancer and the X and CDK that tissue androgen will nonsteroidal presented enobosarm efficacy receptor University trial the consistent X/X the anti-tumor preclinical Professor CDK ARTEST AR can will in it who aromatase recent clinical the receptor in important you ARTEST XXXX. that breast AR met control, negative of staining and to both best is Oncologist breast in receptor Androgen survival. Correlates degree the to study study III receptor the therapy. We Phase at androgen that, breast to cancer The be or III the in with entitled, agent. inhibitor's Palmieri, through X/X CDK introduces with have Breast and presented HERX Degree study Medicine Positive Translational Positivity XXXX and positive by in the restored Phase
the in to FDA cancer targeting enthusiastic First, population. AR diagnostic was target the the androgen we about breast the test receptor with biomarker requested positive, this ER a positive have companion and identify metastatic also important
on based enobosarm guidance, AR evaluate Second, to selected a line the Program is are one targeted regulatory FDA's there two setting. in enobosarm programs. conduct metastatic to third plans monotherapy separate
who We clinical active to control, inhibitor. non-steroidal X/X positive, cancer have AI, exemestane metastatic positive, fulvestrant efficacy enobosarm or evaluate in the SERM will CDK registration Phase versus of ER and breast failed the study negative a III subjects this conduct case HERX with a monotherapy a in AR
is earlier clinical in this subjects study. new moving is CDK the So, to second anticipated therapy, XXX inhibitor approximately combination commence it enobosarm – two And is June plus X/X – XXXX. a in this setting. line evaluate ARTEST Program to metastatic of a it's in
first AI that'll be cancer CDK XXXX. in breast study subjects plus in inhibitor clinical palbo, combination safety AR receptor plus first control We and estrogen failed have XXX X/X to The CDK in a evaluate negative active ER calendar subjects fulvestrant approximately line, receptor efficacy or line this the QX conduct expected case the will in are for agent. and the estrogen alternative commence versus clinical X/X trial an abemaciclib an enobosarm positive, who Phase blocking blocking inhibitor HERX agent positive, is whether II with to it's
cancer Phase start Now, more The month. control pivotal active randomized as focus the follows. is next expected X which on a label, design inhibitor. of six with median and failed let's III the be be free assumptions nonsteroidal are the the An or which fulvestrant enobosarm The exemestane multinational trial X to of survival X/X positive, primary XX% metastatic evaluating dropout – is centrally a this ARTEST multicenter, to is open breast study SERM AI radiographic specifically HERX an endpoint control, oral a be enobosarm will the the – free in statistical approximately months milligrams survival. control who ER is negative choice X have of median efficacy for an AR progression CDK going versus estimated XX% and confirmed will versus radiographic active subjects exemestane sample The physician's active or alpha daily X.XX, size XXX monotherapy With months positive, either rate, safety to subjects. three SERM. and power
We expect enrollment last and to time take XX months the after up XX follow dosed. months recruitment is patient
conducted The in in expect across receptor ARTEST sites clinical United will to Phase be the developed study companion We will partner. company diagnostic States. III the with be that androgen XX the test parallel Phase ARTEST study a III diagnostic large
going excited So, this. on get to
update treatment negative Ib resistant on breast Next, Phase cancer. metastatic I clinical sabizabulin the for you triple of taxane the will chemotherapy evaluating study
of progesterone endocrine to aggressive cancers. or It breast therapies. So, form resistant all cancer estrogen not represents metastatic the triple of negative breast cancer receptor, the is receptor express an form This approximately breast XX% of does breast is HERX cancer.
and systemic represent submit plus Trodelvy efficacy The have at the failed has Ib/II of cancer first negative alone metastasis line three become a inhibits of neutropenia. and administration in of already results human studies IV metastatic chemotherapies, similar IIb has develop a successful, sabizabulin. in of to lung label with [indiscernible] including with Phase oncology We mechanism treatment metastatic antitubulin initiate from evaluate including is and the human sabizabulin, will migration, Unfortunately, no that cancer And resistant an systemic to cell what IV Trodelvy of cancer calendar I indication was QX these that an docetaxel less trials, exhibit almost of usually combination to Paclitaxel, daily a targeted The preclinical for reports proliferation, IND we've a consists non-small plan neutropenia. a eventually In to information an safety significantly whether XXX interesting this is which versus chemotherapies, been study to with with combination IV plinabulin, In induced which if safety all clinical oral arm sabizabulin XXXX. neutropenia IIb is the sabizabulin the negative a prevented open cancer tumor in Trodelvy prostate triple as progression. taxane, be plan approximately of would will docetaxel, of sabizabulin clinical two observed multiple Phase combination trial the clinical invasion. cancer to efficacy, study to with chemotherapy. breast using see shown prostate sabizabulin mentioned, commence taxane, in resistance planned patients studies, better women Phase cancer second It treatment triple with taxane. clinical similar sabizabulin, well breast least tolerated chronic in taxane to colchicine sabizabulin major in
a study. XX and treatment placebo once-daily a sabizabulin of ARDS of sabizabulin distress who oral without high COVID-XX COVID-XX XX respiratory once-daily syndrome. patients syndrome. approach respiratory week, and randomized, proportion the milligrams COVID-XX molecule Phase clinical in placebo-controlled Sabizabulin have Phase virus of the oral to death. hospitalized is this II expect broad of to to with endpoint dose, alive acute risk efficacy distress treatment COVID-XX inflammatory both COVID-XX This two primary trial a we double-blind, antiviral patients lead that is debilitating may The We day patients our small XX. of in setting in activities, dosing failure which at conducted acute versus of subsequent the study, risk with infections III moving enroll high evaluating the hospitalized evaluating and effects the Now to for first serve anti-inflammatory as respiratory a with pronged novel, patient
For n=XX, failure, in sabizabulin treated group, XX% with This sabizabulin reduction n=XX, relative the compared in an the group, failures, treatment the modified primary and proportion to placebo of are sabizabulin patients endpoint in treat population, alive represents to compared the a failures. failure a intent meaningful reduction respiratory day had in dead XX% XX. placebo hospitalized who with patients or clinically treatment to treated in at rate treatment X.X%
at in next The company was from to double high a III group patients COVID-XX of daily from III the of reduction a with Phase XX similar receive the to of agreed treated tolerated is The sabizabulin is II standard COVID-XX ventilation the dosage intend relative was arms both blind, placebo showed and the die statistically to good discuss sabizabulin including placebo endpoint will the X.XX X.X% who X value systemic XX% treated to the blood in the of levels sabizabulin The significant sabizabulin up reduced treat of had expedited will an group. sabizabulin day the of The treated XX. endpoints sabizabulin milligrams efficacy MITT who in to to granted clinically placebo receive on with treated a milligrams FDA doses placebo the upon reduced sabizabulin with sabizabulin Secondary in X hospitalized to sabizabulin study In died patients study p group value Phase sabizabulin profile. placebo. the in and days, in better clinical COVID-XX evaluating that Because meaningful days for who to Sabizabulin design steps, patients population, an program. p X And safety mortality allowed who Phase of in proportion in be trial There II reduction This used placebo for be study. in the days days controlled subjects sabizabulin and placebo ARDS. primary patients subjects to end X.XXX. to oral as milligram of sabizabulin with XXX trial, in XXX XX% formulation a oral versus group ICU, X.X sabizabulin in X will the for on population, multinational, of XXX an the sabizabulin at the mechanical risk days multicenter, with meeting X be randomized trial bioavailability, FDA on X.X the also subjects for days days be will care. versus a the up group. X.XX. will registration Phase proportion XX
mortality. it's So,
by The endpoints mechanical days in the on days from Ordinal study of change for failure, will scale in proportion clinical include without ICU, targeted clinical conducted Mexico Secondary be company III Brazil, The complete the to has Argentina, load. completed the in baseline, drug viral the ventilation, sufficient will days hand to improvement And study. year-end. enrollment be United States, and Colombia. Phase supply and hospital respiratory patients clinical WHO is the on
results try Biomedical needs the to agencies drug and unwilling the Human We hospitalizations Department large commercial assuming get of US and will COVID-XX the to the and unable parts a amount at fund the to of confirmatory Research supply Health Resources, effective to estimated There mutating of the still level. and approval. serious double other and are strains BARDA, of Advanced Development either or mutating to vaccines. US population FDA access and from clinical funding Authority virus population, are of the infection and positive rates seek
the cases hospitalized prevent in focus Phase moderate to COVID-XX clinical It global acute safety that even believe resources Based the development. be for other COVID-XX the believe the though its the pursue this desperately that COVID-XX disease risk an to We III therapy. the in sabizabulin without Phase strongly and anti-inflammatory during we planned II properties sabizabulin We severe clear trial it's cancer COVID-XX at deaths clinical pandemic. strength have for at syndrome conduct since not a start is favorable impacting duty clinical company. highest safe promising with primary is oral needed. with needed indication, level the antiviral of drugs greatly to that global our study, oral and of In patients distress fact, can of the can continues and therapeutic profile are these the respiratory are be on who that persistent pandemic effective to bound results, of company its
our and benign in the combination also accepted approved comment and FDA We BPH TADFIN Xmg developed urology to tadalafil submitted for as April. The tadalafil caused which treat I'll NDA BPH. treatment finasteride lower February. is the symptoms contains of in product NDA erectile Finally, dysfunction FDA product BPH. urinary combination and for Xmg TADFIN the hyperplasia, prostatic for known on by to taxane. tract is finasteride
launched, of date or telemedicine source it We XXXX. via plan additional the will launch December be Veru. TADFIN when to third-party decision PDUFA approved decision for date revenues for TADFIN near-term should Our provide channels. if And
going marketing will So, Michelle? I to have telemedicine. to discuss be we're the done Greco, and over the and a call highlights through turn now Michele not to selling group. CAO, financial CFO It will
